Aggressive Systemic Mastocytosis clinical trials at UC Cancer
1 research study open to new patients
open to eligible people ages 18 years and up
This is a Phase 1, open-label, first-in-human (FIH) dose-escalation study designed to evaluate the safety, tolerability, pharmacokinetics (PK), pharmacodynamics (PD) and preliminary antitumor activity of DCC-2618, administered orally (PO), in adult patients with advanced malignancies. The study consists of 2 parts, a dose-escalation phase and an expansion phase.
at UCLA UCSF